Skip to main content
Skip to footer
Portfolio
Healthcare
Life Sciences
Enterprise
Insights
Team
Strategy
Careers
Contact
Contact
Home
Insights
Our Team
Strategy
Careers
Portfolio
Healthcare
Life Sciences
Enterprise
Contact
Contact
Tag:
Why We Invested
Copernic Catalysts – Why We Invested
March 3, 2025
By Jeff Knox, Senior Associate Each year the world produces more than 180 million metric tonnes of ammonia. An essential…
Why We Invested – Phaseshift Technologies
December 9, 2024
By Matt Fates, Partner, and Eon Mattis, Associate Discovering Next-Generation Materials is Crucial, Yet Complicated For centuries, alloys like steel,…
Why We Invested – Haloo
July 19, 2024
Summary A brand is often a company's most valuable asset. Consider Nike's Swoosh or McDonald's Golden Arches. While trademarking is…
Why We Invested – BioIntelligence
May 23, 2024
By Matt Fates, Partner, and Jeff Knox, Associate Summary The world has grand ambitions to build much of tomorrow’s materials…
Why We Invested – Via Scientfic
January 11, 2024
By Matt Fates, Partner and Jeff Knox, Associate Summary The last two decades have seen tremendous expansion of biological…
Why We Invested – Persist.AI
August 8, 2023
Summary In drug development, new molecular entities get all the press. That’s largely justified – new molecules mean new medicines…
Why We Invested: Antiverse
June 14, 2023
Even before Generative AI caught fire, computationally aided drug discovery was an area of intense interest for researchers. It should…
Portfolio Highlight – Our Investment in Voda.AI
April 11, 2023
By Mark Legare, Senior Associate at Innospark Ventures Certain industries match well with certain founder profiles. A statement as equally…
Why We Invested: Dyania Health
September 21, 2022
By Matt Fates, Partner at Innospark Ventures At any given time, there are roughly 400,000 clinical trials occurring globally. In…
Why We Invested: ODAIA Intelligence
July 7, 2022
As skilled and advanced as the $2T pharma industry is in many regards, there are still key areas where it…